Insperity (NSP) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual Meeting scheduled for May 20, 2025, to vote on four key proposals, including director elections, executive compensation, an amendment to the incentive plan, and auditor ratification.
Board recommends voting in favor of all proposals; proxy materials and annual report are available to shareholders.
Shareholders of record as of April 4, 2025, are eligible to vote; multiple voting methods are available.
Voting matters and shareholder proposals
Four proposals: election of four Class III directors, advisory say-on-pay vote, approval of the First Amendment to the Incentive Plan, and ratification of Ernst & Young LLP as auditor.
Board recommends FOR all proposals; majority of votes cast required for approval.
Shareholder proposals and director nominations for 2026 require advance notice per bylaws.
Board of directors and corporate governance
Board consists of 11 members, with a mix of independent and non-independent directors; diversity in background and expertise is emphasized.
Lead independent director role established; three standing committees: Audit, Compensation, and Nominating & Governance.
Board and committees met regularly in 2024; all directors attended at least 75% of meetings.
Strict policies on hedging and pledging of company stock; code of conduct and annual compliance training in place.
Latest events from Insperity
- Solid Q4 results, resilient profitability, and Workday partnership set stage for 2025 growth.NSP
Q4 20249 Jul 2026 - Q2 2024 saw robust profit growth, but 2024 guidance was cut amid SMB market headwinds.NSP
Q2 20248 Jul 2026 - Margin recovery and cost controls offset lower worksite employee growth and pressured profits.NSP
Q1 20268 Jul 2026 - Proxy seeks approval for director elections, pay, equity plan amendment, and auditor ratification.NSP
Proxy filing14 Apr 2026 - 2026 guidance targets margin recovery and growth, led by HRScale and cost controls.NSP
Q4 202513 Feb 2026 - Q3 net income and EPS dropped sharply, with full-year adjusted EPS guided at $3.42–$3.66.NSP
Q3 202417 Jan 2026 - Higher healthcare costs and economic uncertainty drove lower Q1 earnings despite revenue growth.NSP
Q1 202524 Dec 2025 - Q3 revenue up 4% but net loss and EBITDA fell on higher costs; 2026 recovery expected.NSP
Q3 202513 Nov 2025 - Higher benefits costs drove Q2 profit declines, but 2026 profitability outlook remains strong.NSP
Q2 202531 Oct 2025